The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElı́as Campo, Andrew D. Zelenetz, Ari Melnick et al.|Blood|2022Cited by 1.5k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Owen A. O’Connor et al.|The Lancet Oncology|2010Cited by 852
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J. Gibson, Benjamin L. Ebert, R. Coleman Lindsley et al.|Journal of Clinical Oncology|2017Cited by 468
Non-Hodgkin’s LymphomasAndrew D. Zelenetz, Furhan Yunus, Jeremy S. Abramson et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 329
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Matthew Mei et al.|Journal of Clinical Oncology|2016Cited by 187